SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial.

Kirchhof, P; Ezekowitz, MD; Purmah, Y; Schiffer, S; Meng, IL; Camm, AJ; Hohnloser, SH; Schulz, A; Wosnitza, M; Cappato, R (2020) Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial. TH Open, 4 (1). e20-e32. ISSN 2512-9465 https://doi.org/10.1055/s-0040-1701206
SGUL Authors: Camm, Alan John

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (483kB) | Preview

Abstract

Introduction  This X-VeRT (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) substudy evaluated the effects of treatment with rivaroxaban or a vitamin-K antagonist (VKA) on levels of biomarkers of coagulation (D-dimer, thrombin-antithrombin III complex [TAT] and prothrombin fragment [F1.2]) and inflammation (high sensitivity C-reactive protein [hs-CRP] and high-sensitivity interleukin-6 [hs-IL-6]) in patients with atrial fibrillation (AF) who were scheduled for cardioversion and had not received adequate anticoagulation at baseline (defined as, in the 21 days before randomization: no oral anticoagulant; international normalized ratio <2.0 with VKA treatment; or <80% compliance with non-VKA oral anticoagulant treatment). Methods  Samples for biomarker analysis were taken at baseline ( n  = 958) and treatment completion (42 days after cardioversion; n  = 918). The influence of clinical characteristics on baseline biomarker levels and the effect of treatment on changes in biomarker levels were evaluated using linear and logistic models. Results  Baseline levels of some biomarkers were significantly associated with type of AF (D-dimer and hs-IL-6) and with history of congestive heart failure (hs-CRP, D-dimer, and hs-IL-6). Rivaroxaban and VKA treatments were associated with reductions from baseline in levels of D-dimer (-32.3 and -37.6%, respectively), TAT (-28.0 and -23.1%, respectively), hs-CRP (-12.5 and -17.9%, respectively), and hs-IL-6 (-9.2 and -9.8%, respectively). F1.2 levels were reduced from baseline in patients receiving a VKA (-53.0%) but not in those receiving rivaroxaban (2.7%). Conclusion  Anticoagulation with rivaroxaban reduced levels of key inflammation and coagulation biomarkers to a similar extent as VKAs, with the exception of F1.2. Further investigation to confirm the value of these biomarkers in patients with AF is merited.

Item Type: Article
Additional Information: © 2020 Georg Thieme Verlag KGStuttgart · New York CC BY 4.0
Keywords: anticoagulants, atrial fibrillation, biomarkers, inflammation, rivaroxaban
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: TH Open
ISSN: 2512-9465
Language: eng
Dates:
DateEvent
23 January 2020Published
18 December 2019Accepted
Publisher License: Creative Commons: Attribution 4.0
PubMed ID: 31984306
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/111611
Publisher's version: https://doi.org/10.1055/s-0040-1701206

Actions (login required)

Edit Item Edit Item